ONO PHARMA USA is a pharmaceutical company dedicated to bringing patients innovative medicines across oncology, immunology, neurology, and specialty.
Always Innovative. Always ONO.
ONO PHARMA USA was established in 1998 as the United States subsidiary of ONO PHARMACEUTICAL CO., LTD., a pharmaceutical company founded in Osaka, Japan in 1717. Throughout our history, we have been dedicated to developing novel therapeutics that benefit patients. Our U.S. headquarters are in Cambridge, Mass., an exciting global hub of biotech and biopharmaceutical innovation.
Dedicated to the Fight Against Disease and Pain
Our philosophy captures our longstanding commitment to addressing the most pressing issues in healthcare. ONO is dedicated to advancing medicines that will have meaningful impact on patients, their families, the healthcare system, and wider society.
Be passionate challengers. We wholeheartedly embrace challenges and are fueled by unwavering determination as we harness our unique strengths to develop groundbreaking pharmaceuticals for patients.
- ONO aims to be a world-changing team:
We tackle healthcare challenges that haven’t yet been solved. To do this, we work as an integrated team, bringing together our wisdom, heart, aspirations, and strengths.
- The greater the challenge, the more passionately ONO will rise to meet it:
We will inevitably come up against roadblocks as we undertake important challenges. When we encounter obstacles, we always approach them with ingenuity and follow through with perseverance.
- ONO acts with dignity and pride:
We should never lose the commitment, dedication, and pride we feel working in the pharmaceutical industry. Our goal is to bring hope to those around the world who are waiting for us to deliver solutions.
Guided by ONO’s Global Code of Conduct
Corporate Social Responsibility (CSR)
As part of our commitment to bringing effective therapies to patients who need them, ONO is active in a number of initiatives to support societal and environmental health.
We are always on the lookout for additional opportunities to work on these issues, and we welcome partnerships with organizations who have a similar mission.
20-year-old Ichibei Fushimiya I founds an apothecary in Osaka, with the help of his mentor. This local business, named Fushimiya Ichibei, would one day grow into ONO.
The beginning of the Meiji era brought a new interest in Western medicines. A man named Ichibei Ono, 7th generation, constructed a new shop in Doshomachi, Osaka, where ONO was originally founded.
Ichibei Ono VIII reorganizes the company and changes the name from Fushimiya Ichibei to Ono Ichibei Shoten. It expands into drug manufacturing and begins exploring drug development.
ONO PHARMACEUTICAL Co., Ltd. is established by Ichibei Ono IX (Yuzo Ono) and expands into the over-the-counter market.
ONO is the first company to achieve full prostaglandin synthesis, laying the groundwork for a range of innovative therapeutics.
To expand the company’s global reach, in 1998, ONO PHARMA UK and ONO PHARMA USA are established. In 2013 and 2014, respectively, ONO PHARMA Korea and Taiwan are established.
The world’s first anti-PD-1 antibody, nivolumab, is approved by the FDA. Developed by ONO and Kyoto University, this novel strategy for fighting cancer has changed the treatment paradigm for patients across the globe.
Kunihiko Ito, MBA appointed as CEO of ONO PHARMA USA to help expand the company’s work in the U.S.
ONO PHARMA USA moves its U.S. headquarters from New Jersey to Cambridge, Mass., a global hub of biopharmaceutical and biotech innovation.
ONO PHARMA USA continues to expand its R&D initiatives and commercial capabilities. In the U.S., ONO is currently carrying out clinical trials to investigate potential therapies in two of our focus areas: oncology and neurology.
Meet Our Leaders
Our team of diverse and accomplished leaders come from many professional backgrounds, but have a common goal – to bring innovative medicines to patients who need them.